Sarcoma News and Research

RSS

Researchers suggest new targets may provide druggable alternatives to Ewing's Sarcoma

Ewing's Sarcoma is an aggressive pediatric cancer, most commonly caused by the improper fusion of the gene EWS with the gene FLI1. Though the cause has long been known, therapeutic targeting of this fusion has to date proven very difficult.

22 Jan 2014

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses.

15 Jan 2014

Idiopathic pulmonary fibrosis (IPF) and herpesvirus saimiri: an interview with Elazar Rabbani, Chief Executive Officer of Enzo

Pulmonary fibrosis is a condition where fibrotic or scarred tissue progressively develops in the lungs. In some cases the particular cause is known but in others it remains unknown and is given the term “idiopathic”.

14 Jan 2014

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Rex Marco, M.D., professor in the Department of Orthopaedic Surgery at The University of Texas Health Science Center at Houston Medical School, is the recipient of an award recognizing excellence in the treatment of a type of cancer called sarcoma.

14 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

EORTC hosts joint session with ESTRO to focus on latest developments in soft tissue sarcoma treatment

The EORTC will host a joint session with ESTRO at ESTRO 33 focusing on current developments in soft tissue sarcoma treatment. It will take place from 14:30- 16:00 on Monday, 07 April 2014 in Vienna, Austria and will be co-chaired by Professors Jean-Yves Blay of the Centre Leon Berard in Lyon, France and past EORTC President and Philippe Maingon of the Centre Georges-Fran-ois-Leclerc in Dijon, France, and Chair of the EORTC Radiation Oncology Group.

3 Dec 2013

Serametrix launches new MDSC-based blood test for cancer patients

Serametrix Corporation has announced the launch of an important new blood test for cancer patients. The test measures a patient's level of circulating Myeloid Derived Suppressor Cells (MDSCs) that are known to decrease anti-tumor immunity and are associated with poor survival rates in cancer patients.

20 Nov 2013

Professor receives NOK 75M grant to develop idea for next generation personalized cancer therapy

Extensive statistical analyses of the mutation distribution in several thousand cancerous tumours make it possible to find cures for types of cancer that cannot be treated today.

13 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Nanomedicine Award winners officially announced at BIO-Europe conference

The winners of the first ever Nanomedicine Award were officially announced during the Nanomedicine Panel at BIO-Europe conference in Vienna, November 4th 2013. The Award review Board agreed to distinguish two projects in two different categories: The winners are Endomagnetics Ltd in the nanodiagnostic category and the I-CARE project from Linköping University in the regenerative medicine category.

4 Nov 2013

Study: Dual-pronged strategy could successfully treat childhood cancer

A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, finds a new study.

3 Nov 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

Two related genes underlie development of two rare bone tumours in nearly 100% of patients

Scientists have made a rare discovery that allows them to attribute two types of tumour almost entirely to specific mutations that lie in two related genes.

28 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013

NIH Getting Back To Business As Shutdown Ends

...

17 Oct 2013

Evidence shows vaccination pilot campaigns highly successful during 2010 cholera epidemic

The deadly cholera epidemic that rocked earthquake-shattered Haiti in 2010, claiming 8,000 lives and counting, has rallied the public health community to seek water and sewer improvements that, combined with vaccination, could prevent some 89,000 future cholera infections.

11 Oct 2013

NIH program provides $22M for low- and middle-income countries to combat HIV/AIDS epidemic

A new NIH program supporting HIV-related research training will provide $22 million over five years for activities in 15 low- and middle-income countries. The Fogarty International Center's HIV Research Training Program is issuing 22 awards, which are intended to strengthen the ability of the grantee institutions to combat the HIV/AIDS epidemic, while building expertise in a particular scientific or critical research infrastructure area.

27 Sep 2013

Proton therapy reduces treatment side effects among head and neck cancer patients

The precise targeting and limited dosing of radiation via proton therapy is proving to be an advantage in ongoing efforts to reduce treatment side effects among head and neck cancer patients, according to a new study of pediatric patients from researchers at the Perelman School of Medicine at the University of Pennsylvania.

25 Sep 2013

Pancreatic Cancer Imaging Agent Earns Mabvax $1.75M SBIR Award

...

24 Sep 2013